Profile data is unavailable for this security.
About the company
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacs’ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
- Revenue in NOK (TTM)0.00
- Net income in NOK-177.88m
- Incorporated2011
- Employees25.00
- LocationUltimovacs ASAUllernchausseen 64OSLO 0379NorwayNOR
- Websitehttps://ultimovacs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thor Medical ASA | 0.00 | -5.56m | 237.68m | 1.00 | -- | 0.8691 | -- | -- | -0.0318 | -0.152 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -2.52 | -79.17 | -2.84 | -113.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Abliva AB | 136.59k | -95.22m | 239.46m | 6.00 | -- | 2.66 | -- | 1,753.22 | -0.0904 | -0.0904 | 0.0001 | 0.067 | 0.001 | -- | 0.0034 | -- | -70.40 | -74.59 | -80.95 | -86.98 | -14,491.24 | -- | -69,714.60 | -65,958.89 | -- | -- | 0.00 | -- | 341.94 | 93.89 | -12.02 | -- | -19.74 | -- |
| Corline Biomedical AB | 21.31m | -4.48m | 243.18m | 13.00 | -- | 2.66 | -- | 11.41 | -0.2092 | -0.2092 | 0.9944 | 4.26 | 0.2089 | -- | 6.96 | 1,643,846.00 | -4.39 | -5.71 | -4.80 | -6.24 | 115.99 | 128.60 | -21.04 | -38.46 | -- | -235.63 | 0.00 | -- | 6.28 | 74.14 | -177.67 | -- | 62.51 | -- |
| Exact Therapeutics AS | 0.00 | -48.33m | 247.02m | 8.00 | -- | 5.48 | -- | -- | -1.51 | -1.51 | 0.00 | 1.41 | 0.00 | -- | -- | -- | -67.21 | -40.21 | -86.14 | -45.67 | -- | -- | -- | -- | -- | -16,578.57 | 0.0258 | -- | -- | -- | -20.52 | -- | -- | -- |
| Scandion Oncology A/S | 0.00 | -57.16m | 250.34m | 4.00 | -- | 2.22 | -- | -- | -0.4311 | -0.4311 | 0.00 | 0.2684 | 0.00 | -- | -- | 0.00 | -74.59 | -- | -87.90 | -- | -- | -- | -- | -- | -- | -- | 0.0113 | -- | -- | -- | 48.89 | -- | -- | -- |
| Arctic Bioscience AS | 33.75m | -45.51m | 261.31m | 20.00 | -- | 1.01 | -- | 7.74 | -1.79 | -1.79 | 1.33 | 10.19 | 0.1075 | 0.7025 | 2.93 | 1,687,501.00 | -14.50 | -- | -16.61 | -- | 28.96 | -- | -134.86 | -- | 2.53 | -- | 0.0079 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| Saniona AB | 16.79m | -95.52m | 266.72m | 23.00 | -- | -- | -- | 15.89 | -1.29 | -1.29 | 0.2263 | -0.2895 | 0.1546 | -- | 4.71 | 732,173.90 | -87.96 | -59.16 | -108.11 | -70.15 | -213.08 | -970.05 | -568.94 | -1,483.55 | -- | -3.18 | 1.44 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
| SynAct Pharma AB | 0.00 | -190.26m | 279.96m | 5.00 | -- | 1.59 | -- | -- | -5.65 | -5.65 | 0.00 | 4.28 | 0.00 | -- | -- | 0.00 | -71.43 | -125.17 | -79.52 | -151.70 | -- | -- | -- | -- | -- | -853.13 | 0.0033 | -- | -- | -- | -117.54 | -- | -- | -- |
| InDex Pharmaceuticals Holding AB | 108.01m | -56.31m | 280.41m | 7.00 | -- | 1.19 | -- | 2.60 | -0.1037 | -0.1037 | 0.2028 | 0.443 | 0.3559 | -- | -- | 15,477,000.00 | -18.55 | -37.64 | -21.24 | -41.14 | -46.98 | -450.51 | -52.13 | -454.62 | -- | -- | 0.0086 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
| Intervacc AB | 8.90m | -102.45m | 295.23m | 15.00 | -- | 1.34 | -- | 33.18 | -1.40 | -1.40 | 0.1221 | 2.91 | 0.0365 | 3.25 | 1.55 | 595,066.70 | -41.96 | -17.62 | -45.32 | -18.77 | -589.11 | -243.59 | -1,151.30 | -626.90 | 4.33 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Ultimovacs ASA | 0.00 | -177.88m | 309.65m | 25.00 | -- | 1.19 | -- | -- | -5.17 | -5.17 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -44.31 | -28.80 | -50.09 | -31.12 | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Lytix Biopharma AS | 3.99m | -87.90m | 317.51m | 10.00 | -- | 5.07 | -- | 79.56 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.0368 | -- | 0.4091 | 399,100.00 | -80.96 | -56.91 | -94.07 | -65.83 | -- | -- | -2,202.36 | -771.78 | -- | -- | 0.0095 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
| Ascelia Pharma AB | 0.00 | -88.49m | 354.06m | 13.00 | -- | 5.83 | -- | -- | -2.63 | -2.63 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -65.17 | -- | -78.39 | -- | -- | -- | -- | -- | -- | -- | 0.2302 | -- | -- | -- | 16.72 | -- | -- | -- |
| Medivir AB | 7.71m | -96.23m | 360.84m | 10.00 | -- | 1.71 | -- | 46.80 | -1.46 | -1.46 | 0.1028 | 1.89 | 0.032 | -- | 1.56 | 773,300.00 | -40.00 | -28.91 | -47.20 | -34.77 | -888.81 | -467.42 | -1,248.18 | -675.96 | -- | -- | 0.0482 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| Magle Chemoswed Holding AB | 169.50m | 12.19m | 363.93m | 78.00 | 29.85 | 2.26 | 14.57 | 2.15 | 1.13 | 1.13 | 15.74 | 14.95 | 0.6068 | 0.493 | 8.30 | 2,179,628.00 | 4.36 | 2.52 | 5.86 | 3.52 | 90.58 | 85.67 | 7.19 | 3.92 | 0.6356 | 6.35 | 0.3081 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| INIFY Laboratories AB | 3.41m | -51.20m | 379.96m | 23.00 | -- | 5.22 | -- | 111.54 | -1.13 | -1.13 | 0.0753 | 1.61 | 0.032 | 2.99 | 0.6608 | -- | -48.10 | -- | -48.10 | -- | 76.42 | -- | -1,503.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Ultimovacs ASA's reporting currency: Norwegian Krone NOK
11.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Folketrygdfondetas of 14 Sep 2023 | 1.28m | 3.72% |
| Nordea Investment Management AB (Norway)as of 26 Mar 2024 | 707.18k | 2.06% |
| Handelsbanken Fonder ABas of 30 Apr 2024 | 386.04k | 1.12% |
| Sissener ASas of 14 Sep 2023 | 369.72k | 1.08% |
| KLP Kapitalforvaltning ASas of 31 Mar 2023 | 348.42k | 1.01% |
| Danske Invest Asset Management ASas of 30 Apr 2024 | 246.03k | 0.72% |
| Equinor Asset Management ASAas of 31 Dec 2023 | 161.48k | 0.47% |
| DNB Asset Management ASas of 27 Mar 2024 | 156.84k | 0.46% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 142.36k | 0.41% |
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 68.71k | 0.20% |
More ▼
Data from 30 Jun 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
